Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

E-Poster Display

1290P - Efficacy and safety with selpercatinib by last prior systemic therapy received in patients (Pts) with RET fusion + non-small cell lung cancer (NSCLC)

Date

17 Sep 2020

Session

E-Poster Display

Presenters

Oliver Gautschi

Citation

Annals of Oncology (2020) 31 (suppl_4): S754-S840. 10.1016/annonc/annonc283

Authors

O. Gautschi1, A. Drilon2, D.S.W. Tan3, G.R. Oxnard4, C.E. McCoach5, K. Goto6, K. Park7, G. Alonso Casal8, F. de Braud9, P. French10, V. Soldatenkova11, B. Besse12

Author affiliations

  • 1 Medical Oncology, Luzerner Kantonsspital, 6004 - Luzern/CH
  • 2 Early Drug Development, Memorial Sloan Kettering Cancer Center, 10065 - New York/US
  • 3 Division Of Medical Oncology, National Cancer Centre Singapore, 169610 - Singapore/SG
  • 4 Medical Oncology, Dana Farber Cancer Institute, 02215 - Boston/US
  • 5 Medical Oncology, UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco/US
  • 6 Department Of Thoracic Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 7 Div. Of Heamatology/oncology, Medicine, Samsung Medical Center (SMC)-Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 8 Medical Oncology Department, Vall d'Hebron University Hospital, 08035 - Barcelona/ES
  • 9 Oncolgia Medica Ed Ematologia, Istituto Nazionale Tumori Milano, Milan/IT
  • 10 Oncology, Eli Lilly and Company - Global Headquarters, 46285 - Indianapolis/US
  • 11 Oncology, Eli Lilly and Company, 46285 - INDIANAPOLIS/US
  • 12 Dept Of Cancer Medicine, Institut Gustave Roussy, 94805 - Villejuif/FR
More

Resources

Abstract 1290P

Background

Selpercatinib (LOXO-292), a highly selective and potent RET kinase inhibitor, demonstrated marked and durable antitumor activity in pts with RET fusion+ NSCLC in an ongoing phase 1/2 trial. We evaluated best responses to last prior therapy received before enrollment and to selpercatinib by last prior therapy subgroups.

Methods

Pts with RET fusion+ NSCLC enrolled in the global, multicenter, LIBRETTO-001 trial (NCT03157128) received the recommended phase 2 selpercatinib dose (160 mg twice daily) after dose escalation. This analysis assessed outcomes by category of last systemic therapy received prior to enrollment. Efficacy was analyzed in the first 105 consecutively enrolled pts pretreated with platinum chemotherapy (primary analysis set [PAS]). Adverse events (AEs) were measured in all pretreated pts who received selpercatinib by data cutoff date of 16-Dec-2019.

Results

PAS pts (n=105) had a median of 3 (range: 1-15) prior systemic regimens. Most pts received chemotherapy only (30%) or a multikinase inhibitor (MKI) (32%), and had an objective response rate (ORR) with these regimens of 13% and 18%, respectively (Table). ORR with selpercatinib was 64% (95% CI: 53.9-73.0) regardless of previous regimen type and ranged from 58% to 69% across prior therapy groups (Table). In the pretreated safety population (n=269), the most common treatment-related AEs reported in ≥1 prior therapy groups in ≥20% of pts were diarrhea, dry mouth, increased AST or ALT, rash, fatigue, thrombocytopenia, peripheral edema, increased blood creatinine or blood alkaline phosphate, and hypertension. Table: 1290P

Prior Chemo Only (n=31) Prior ICI Only (n=14) Prior Chemo + ICI (n=10) Prior MKI (n=34) Prior Other Combination (n=16)
Best response to last prior systemic therapy received before enrollment
ORR, % 13 7 20 18 13
Best response (by IRC) to selpercatinib
ORR, % (95% CI), n 58 (39.1–75.5), 18 64 (35.1–87.2), 9 60 (26.2–87.8), 6 68 (49.5–82.6), 23 69 (41.3–89.0), 11
DoR, median (95% CI), months 18 (6.5, NE) – (8.3, NE) – (7.7, NE) 12 (12.0, NE) – (11.0, NE)
Duration of follow-up, median, months 13 14 9 12 12

Abbreviations: Chemo, chemotherapy; DoR, duration of response; ICI, immune checkpoint inhibitor; IRC, independent review committee; MKI, multikinase inhibitor; NE, not evaluable; ORR, objective response rate.

Conclusions

Pts enrolled in LIBRETTO-001 did not experience clinically meaningful ORRs to varied therapies administered prior to selpercatinib. By contrast, selpercatinib showed consistent, robust, and durable efficacy across these varied prior therapy histories in heavily pretreated pts with RET fusion+ NSCLC. There were no new safety signals.

Clinical trial identification

EudraCT Number: 2017-000800-59. Date on which this record was first entered in the EudraCT database: 05-07-2018. Per Eli Lily and Company policy, results will be posted within 1 year of the primary outcome and trial completion actual dates. The estimated study completion date is May 2022 and the estimated primary completion date is March 2022.

Editorial acknowledgement

The authors acknowledge Karen Paulsrud, RPh, with Eli Lilly and Company, for editorial assistance in the writing of the abstract.

Legal entity responsible for the study

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company.

Funding

Loxo Oncology, Inc., a wholly owned subsidiary of Eli Lilly and Company.

Disclosure

O. Gautschi: Advisory/Consultancy: Amgen. A. Drilon: Honoraria (self), Advisory/Consultancy: Ignyta, Genentech, Roche, Loxo, Bayer, Lilly, Takeda, Ariad, Millenium, TP Therapeutics, AstraZeneca, Pfizer, Blueprint Medicines, Helsinn, Beigene, BergenBio, Hengrui Therapeutic, Exelixis, Tyra Biosciences, Verastem, MORE Health, AbbVie, 14ner, Elevatio; Research grant/Funding (institution): Pfizer, Exelixis, GlaxoSmithKlein, Teva, Taiho, PharmaMar, ; Research grant/Funding (self): Foundation Medicine; Licensing/Royalties: Wolters Kluwer; Travel/Accommodation/Expenses: Merck, Puma, Merus, Boehringer Ingelheim; Honoraria (self), CME: Medscape, OncLive, PeerVoice, Physicians Education Resources, Targeted Oncology, Research to Practice, Axis, Peerview Institute, Paradigm Medical Communications, WebMD. D.S.W. Tan: Advisory/Consultancy: Novartis, Merck, Loxo, AstraZeneca, Roche, Pfizer; Travel/Accommodation/Expenses: Pfizer, Boehringer Ingelheim, Roche; Honoraria (self): Bristol-Myers Squibb, Takeda, Novartis, Roche, Pfizer, Novartis; Research grant/Funding (institution): Novartis, GlaxoSmithKline, AstraZeneca. G.R. Oxnard: Advisory/Consultancy: AstraZeneca, Inivata, Takeda, Loxo, DropWorks, GRAIL, Janssen, Sysmex, Illumina, AbbVie, Merck; Licensing/Royalties, Patent pending entitled, \"Non-invasive blood-based monitoring of genomic alterations in cancer,\" on which Dr. Oxnard is a co-author.: Dana-Farber Cancer Institute; Honoraria (self): Sysmex, Guardant Health, Foundation Medicine. C. McCoach: Honoraria (self), Speaker Bureau/Expert testimony, Research grant/Funding (self): Novartis; Travel/Accommodation/Expenses: Loxo, Lilly, Takeda; Research grant/Funding (self): Revolution Medicines. K. Goto: Advisory/Consultancy: Otsuka; Honoraria (self): Bristol-Myers Squibb, AstraZeneca, Pfizer, Chugai Pharma, Taiho Pharmaceutical, Ono Pharmaceutical, Novartis, Lilly, Boehringer Ingelheim, Life Technologies, MSD, Nippon Kayaku, Takeda, Otsuka, IQVIA, Astellas Pharma, Guardant Health, Janssen, Kyowa Hakko; Research grant/Funding (self): MSD, AstraZeneca, Taiho Pharmaceutical, Chugai Pharma, Boehringer Ingelheim, Ono Pharmaceutical, Sumitomo Dainippon Pharma, Takeda, Novartis, Daiichi Sankyo, Kyowa Hakko Kirin, Astellas Pharma, Eisai, Lilly, Pfizer, Riken Genesis, Bristol-Myers Squibb, Me. K. Park: Advisory/Consultancy: AstraZeneca, Boehringer Ingelheim, Lilly, Hanmi, Novartis, Ono Pharmaceutical, Roche, Bristol-Myers Squibb, MSD, Blueprint Medicines, Amgen, Merck KGaA, Loxo, AbbVie, Daiichi Sankyo, ; Speaker Bureau/Expert testimony: Boehringer Ingelheim, AZD; Research grant/Funding (self): AstraZeneca, MSD Oncology. F. de Braud: Advisory/Consultancy: Ignyta, BMS, Daiichi Sankyo, Pfizer, Octimet Oncology, Incyte, Teofarma, Pierre Fabre, Roche, EMD Serono, Sanofi, NMS Neviano Medical Science, Pharm Research Associated (U.K.) Ltd.; Speaker Bureau/Expert testimony: BMS, Roche, MSD, Ignyta, Bayer, ACCMED, Dephaforum S.r.l., Nadirex, Merck, Biotechspert Ltd, PriME Oncology, Pfizer, Servier, Celgene, Tesaro, Loxo Oncology Inc., Sanofi, Healthcare Research & Pharmacoepidemiology; Research grant/Funding (self): Novartis, Roche, BMS, Celgene, Incyte, NMS, Merck KGAA, Kymab, Pfizer, Tesaro, MSD. P. French: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly and Company. V. Soldatenkova: Shareholder/Stockholder/Stock options, Full/Part-time employment: Eli Lilly and Company. B. Besse: Research grant/Funding (institution): AstraZeneca, Pfizer, Lilly, Onxeo, Bristol-Myers Squibb, Inivata, AbbVie, Amgen, Blueprint Medicines, Celgene, GlaxoSmithKline, Ignyta, Ipsen, Merck KGaA, MSD Oncology, Nektar, PharmaMar, Sanofi, Spectrum Pharmaceuticals, Takeda, Tiziana Therapeutics, Cri. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings